// App-Quantinova.ai

P1-09-04 : Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies

Researchers

Presenter

  • G Bianchini

Principal Investigators

  • T Pienkowski

  • Y-H Im

  • GV Bianchi

  • L-M Tseng

  • M-C Liu

  • A Lluch

  • J de la Haba-Rodríguez

  • V Semiglazov

  • D-Y Oh

  • B Poirier

  • JL Pedrini

  • P Valagussa

  • L Gianni

Medical Centers

  • Centrum Onkologii, Warsaw, Poland

  • IRCCS Ospedale San Raffaele, Milan, Italy

  • Hospital Clinico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain

  • Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Hopital du Saint-Sacrement, CHU de Quebec, Quebec, Quebec, Canada

  • Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan

  • Hospital Ernesto Dornelles, Porto Alegre, Brazil

  • Fondazione Michelangelo, Milan, Italy

  • University Hospital Reina Sofia, Cordoba, Spain

Locations

  • Brazil

  • Canada

  • Taiwan

  • Italy

  • Poland

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Cyclin dependent kinase inhibitor 1A

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Trastuzumab

  • Pertuzumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • randomized

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved